Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Purchased by Rhumbline Advisers

Rhumbline Advisers boosted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 3.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 180,274 shares of the specialty pharmaceutical company’s stock after acquiring an additional 5,813 shares during the period. Rhumbline Advisers owned about 0.33% of Supernus Pharmaceuticals worth $4,822,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of the stock. Fidelis Capital Partners LLC purchased a new stake in shares of Supernus Pharmaceuticals in the 1st quarter valued at about $33,000. EntryPoint Capital LLC purchased a new stake in Supernus Pharmaceuticals in the first quarter valued at approximately $43,000. Quadrant Capital Group LLC boosted its holdings in shares of Supernus Pharmaceuticals by 1,117.6% in the fourth quarter. Quadrant Capital Group LLC now owns 1,449 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 1,330 shares during the period. Innealta Capital LLC purchased a new position in shares of Supernus Pharmaceuticals during the second quarter worth approximately $51,000. Finally, nVerses Capital LLC acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $72,000.

Supernus Pharmaceuticals Trading Up 0.7 %

NASDAQ:SUPN opened at $31.11 on Monday. Supernus Pharmaceuticals, Inc. has a 12-month low of $21.99 and a 12-month high of $35.44. The stock’s 50 day simple moving average is $31.69 and its 200-day simple moving average is $30.40. The firm has a market cap of $1.71 billion, a P/E ratio of -107.28 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by ($0.03). Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The firm had revenue of $168.30 million during the quarter, compared to analyst estimates of $148.83 million. During the same period in the prior year, the firm posted ($0.02) earnings per share. The business’s quarterly revenue was up 24.1% compared to the same quarter last year. Research analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SUPN has been the subject of a number of recent research reports. Piper Sandler cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $41.00 to $36.00 in a research note on Wednesday, September 11th. StockNews.com upgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.